Journal issues > Issue 1, February 2019 > Highlights in myelodysplastic syndromes

Highlights in myelodysplastic syndromes

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic malignancies characterized by peripheral blood cytopenias resulting from ineffective hematopoiesis. MDS is associated with a risk for progression to acute myeloid leukemia (AML). Progress in the field of this disease aims at decreasing the transfusion burden, delaying progression to AML, improving the quality-of-life (QoL) of patients and extending the survival. Here, we report some recent advances presented at the 60^th Annual Meeting of the American Society of Hematology (ASH).

(BELG J HEMATOL 2019;10(1):24–30)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top